PCRX Q2 2020 Earnings — Pacira BioSciences, Inc. Revenue & Financial Results | Market Cap Arena

PCRXPacira BioSciences, Inc.

$969M

Q2 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$76M-26.4% YoY

Gross Profit

$53M70.5% margin

Operating Income

-$7M-9.5% margin

Net Income

-$7M-9.6% margin

EPS (Diluted)

$-0.17

QoQ Revenue Growth

-28.6%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$25M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$866M

Total Liabilities

$478M

Stockholders' Equity

$388M

Cash & Equivalents

$79M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$76M	$103M	-26.4%
Gross Profit	$53M	$77M	-31.3%
Operating Income	-$7M	$5M	-235.5%
Net Income	-$7M	$3M	-366.3%

Revenue Segments

Product

$75M100%

Royalty

$289,0000%